Immunotherapy Shows Activity Among Patients With Gynecologic Clear Cell Carcinoma
Don Dizon, MD, Lifespan Cancer Institute, Providence, Rhode Island, shares insights from the phase 2 BrUOG 354 trial evaluating nivolumab with or without ipilimumab among patients with ovarian and extra-renal clear cell carcinomas.
According to Dr Dizon and coauthors, nivolumab plus ipilimumab “warrant further evaluation against standard treatment for people with ovarian [clear cell carcinoma], given the historically chemotherapy-resistant nature of the disease.
Source:
Dizon D, Mathews CA, MacLaughlan David S, et al. Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas. Presented at the ASCO Annual Meeting. May 31 – June 4, 2024; Chicago, IL. Abstract #LBA5500